Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).
By M. Extermann, M. Aapro, R. Bernabei, H. Cohen, J. Droz, S. Lichtman, V. Mor, S. Monfardini, L. Repetto, L. Sørbye and 1 more. Critical reviews in oncology/hematology, 2005
1,079 citations recorded by the source corpus.
Subfields: Critical Care and Intensive Care Medicine, Geriatrics and Gerontology, Physiology
View Paper: https://www.semanticscholar.org/paper/9989c6a12a3f31cfb0fbe6942b6224cd3164a7d1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. Mohile
- H. Wildiers
- L. Decoster
- P. Heeren
- J. Bellmunt
- M. Extermann
- K. Puyvelde
- M. Puts
Citations in the corpus
- International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. (2014, background): “The International Society of Geriatric Oncology (SIOG) established recommendations on GA in older patients with cancer in 2005.(13) Numerous publications have emerged during the subsequent years.”
- Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. (2015, methodology): “In 2005, SIOG recommended the use of screening tools in cancer patients aged 70 years or older, but in the absence of tools tested in this population, no specific tool was recommended [1].”
- Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. (2012, background): “As previously discussed,(19) comprehensive geriatric assessment tools have been recommended by several societies and might be integrated into study designs to better select elderly patients with bladder cancer (those older than age 70 years) for trials and different schedules of treatment.(37-39) In”